Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Fertility Treatment Indications for 9 Meds to Be Reported to PAFSC Panel on March 9
February 25, 2022
- Therapeutic App for Hypertension Up for PAFSC Review on March 9
February 24, 2022
- Bill to Amend PMD Law Set for Cabinet Approval as Early as March 1
February 24, 2022
- Xevudy Delivery for 80,000 People Begins Ahead of Schedule: Health Minister
February 24, 2022
- No Reasonable Link between COVID-19 Vaccinations and Excess Deaths: MHLW Panels
February 22, 2022
- PMDA Reviewing New Safety Risks for Brilinta, Stocrin, Ofev
February 21, 2022
- All Company-Led Post-Marketing Studies Should Be Regulated by PMD Law upon Clinical Research Law Amendment: Panel
February 21, 2022
- Japan Weighs Pre-Approval Purchase of Shionogi’s COVID-19 Pill
February 21, 2022
- AZ’s Asthma Drug, Takeda HAE Med, Novartis CML Therapy and More Up for PAFSC Review on March 3
February 18, 2022
- Komeito Hears Update on Mitsubishi Tanabe’s COVID-19 Vaccine
February 18, 2022
- LDP Health Committee OKs Bill to Amend PMD Law
February 18, 2022
- Key Resource Suppliers to Be Fined for False Reporting: Draft Economic Security Bill
February 17, 2022
- MHLW Flags Xevudy Supply Disruption, Calls for Use of Other COVID-19 Drugs
February 17, 2022
- MHLW Calls for Considering Veklury Use as Tight Supply Expected for Xevudy
February 16, 2022
- Lawmakers Mixed on Use of Conditional Approval for Shionogi’s COVID-19 Pill
February 16, 2022
- Japan Approves Slew of Generics towards June Listing; Samsca, Xarelto AGs Too
February 16, 2022
- Japan Snags 10 Million Extra Doses of Pfizer Vaccine
February 15, 2022
- Japan Panel OKs Free COVID-19 Vaccination for Ages 5-11, but No “Effort” Obligation Applied
February 14, 2022
- MHLW Panel to Review Bayer’s CKD Drug Finerenone Again on Feb. 25
February 14, 2022
- Pfizer’s Paxlovid Contraindicated with Many Medicines, Requires Careful Use
February 14, 2022
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…